The role of ghrelin signalling in second-generation antipsychotic-induced weight gain

Psychoneuroendocrinology

Volumn 38, Issue 11, 2013, Pages 2423-2438

  Zhang, Qingsheng ^a   Deng, Chao ^a,b   Huang, Xu Feng ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

AMPK; Antipsychotic; Ghrelin; Hypothalamus; Neuropeptides; Obesity

Indexed keywords

CLOZAPINE; GHRELIN; GHRELIN RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARCUATE NUCLEUS; BLOOD BRAIN BARRIER; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; DRUG SAFETY; FOOD INTAKE; HORMONAL REGULATION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; NERVE CELL NETWORK; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT DURATION; UPREGULATION; WEIGHT GAIN;

AMPK; ANTIPSYCHOTIC; GHRELIN; HYPOTHALAMUS; NEUROPEPTIDES; OBESITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; GHRELIN; HUMANS; SIGNAL TRANSDUCTION; WEIGHT GAIN;

EID: 84886100577     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.07.010     Document Type: Review

References (118)

1. Adachi S., Takiguchi S., Okada K., Yamamoto K., Yamasaki M., Miyata H., Nakajima K., Fujiwara Y., Hosoda H., Kangawa K., Mori M., Doki Y. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology 2010, 138:1312-1320.
2. Albaugh V.L., Henry C.R., Bello N.T., Hajnal A., Lynch S.L., Halle B., Lynch C.J. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity 2006, 14:36-51.
3. Albaugh V.L., Judson J.G., She P., Lang C.H., Maresca K.P., Joyal J.L., Lynch C.J. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol. Psychiatr. 2011, 16:569-581.
4. Andrews Z.B. Central mechanisms involved in the orexigenic actions of ghrelin. Peptides 2011, 32:2248-2255.
5. Andrews Z.B. The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci. 2011, 34:31-40.
6. Andrews Z.B., Liu Z.-W., Walllingford N., Erion D.M., Borok E., Friedman J.M., Tschop M.H., Shanabrough M., Cline G., Shulman G.I., Coppola A., Gao X.-B., Horvath T.L., Diano S. UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 2008, 454:846-851.
7. Arnold M., Mura A., Langhans W., Geary N. Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J. Neurosci. 2006, 26:11052-11060.
8. Asakawa A., Inui A., Kaga O., Yuzuriha H., Nagata T., Ueno N., Makino S., Fujimiya M., Niijima A., Fujino M.A., Kasuga M. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001, 120:337-345.
9. Asakawa A., Inui A., Kaga T., Katsuura G., Fujimiya M., Fujino M.A., Kasuga M. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003, 52:947-952.
10. Banks W.A., Tschöp M., Robinson S.M., Heiman M.L. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J. Pharmacol. Exp. Ther. 2002, 302:822-827.
11. Basoglu C., Oner O., Gunes C., Semiz U.B., Ates A.M., Algul A., Ebrinc S., Cetin M., Ozcan O., Ipcioglu O. Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. Int. Clin. Psychopharmacol. 2010, 25:165-171.
12. Beck B., Richy S., Stricker-Krongrad A. Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci. 2004, 76:473-478.
13. Bednarek M.A., Feighner S.D., Pong S.-S., McKee K.K., Hreniuk D.L., Silva M.V., Warren V.A., Howard A.D., Van der Ploeg L.H.Y., Heck J.V. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. 2000, 43:4370-4376.
14. Bhugra D. The global prevalence of schizophrenia. PLoS Med. 2005, 2:e151.
15. Broglio F., Gottero C., Van Koetsveld P., Prodam F., Destefanis S., Benso A., Gauna C., Hofland L., Arvat E., van der Lely A.J., Ghigo E. Acetylcholine regulates ghrelin secretion in humans. J. Clin. Endocr. Metab. 2004, 89:2429-2433.
16. Castaneda T.R., Tong J., Datta R., Culler M., Tschop M.H. Ghrelin in the regulation of body weight and metabolism. Front. Neuroendocrinol. 2010, 31:44-60.
17. Chen C.Y., Chao Y., Chang F.Y., Chien E.J., Lee S.D., Doong M.L. Intracisternal des-acyl ghrelin inhibits food intake and non-nutrient gastric emptying in conscious rats. Int. J. Mol. Med. 2005, 16:695-699.
18. Chen V.C.-H., Wang T.-N., Lu M.-L., Chou J.-Y., Ju P.-C., Wu J.-Y., Lin Z.-R., Ji T.-T., Chou C.-E., Lee C.-T., Lai T.-J. Weight gain and ghrelin level after olanzapine monotherapy. Prog. Neuro Psychopharmacol. 2011, 35:632-635.
19. Choi K., Roh S.-G., Hong Y.-H., Shrestha Y.B., Hishikawa D., Chen C., Kojima M., Kangawa K., Sasaki S.-I. The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. Endocrinology 2003, 144:754-759.
20. Couchman L., Morgan P.E., Spencer E.P., Flanagan R.J. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther. Drug Monit. 2010, 32:438-447.
21. Cowley M.A., Smith R.G., Diano S., Tschöp M., Pronchuk N., Grove K.L., Strasburger C.J., Bidlingmaier M., Esterman M., Heiman M.L., Garcia-Segura L.M., Nillni E.A., Mendez P., Low M.J., Sotonyi P., Friedman J.M., Liu H., Pinto S., Colmers W.F., Cone R.D., Horvath T.L. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003, 37:649-661.
22. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., Kangawa K., Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002, 123:1120-1128.
23. Davey K.J., O'Mahony S.M., Schellekens H., O'Sullivan O., Bienenstock J., Cotter P.D., Dinan T.G., Cryan J.F. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berlin) 2012, 221:155-169.
24. Davies M.A., Compton-Toth B.A., Hufeisen S.J., Meltzer H.Y., Roth B.L. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?. Psychopharmacology (Berlin) 2005, 178:451-460.
25. Deng C., Weston-Green K., Huang X.-F. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog. Neuro Psychopharmacol. 2010, 34:1-4.
26. Druce M.R., Wren A.M., Park A.J., Milton J.E., Patterson M., Frost G., Ghatei M.A., Small C., Bloom S.R. Ghrelin increases food intake in obese as well as lean subjects. Int. J. Obes. Relat. Metab. Disord. 2005, 29:1130-1136.
27. Elman I., Borsook D., Lukas S.E. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006, 31:2091-2120.
28. Esen-Danaci A., Sarandöl A., Taneli F., Yurtsever F., Ozlen N. Effects of second generation antipsychotics on leptin and ghrelin. Prog. Neuro Psychopharmacol. 2008, 32:1434-1438.
29. Evers S.S., Calcagnoli F., van Dijk G., Scheurink A.J.W. Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats. Pharmacol. Biochem. Behav. 2010, 97:163-169.
30. Fernø J., Varela L., Skrede S., Vázquez M.J., Nogueiras R., Diéguez C., Vidal-Puig A., Steen V.M., López M. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE 2011, 6:e20571.
31. Fetissov S.O., Meguid M.M., Sato T., Zhang L.-H. Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. Am. J. Physiol., Regul. Integr. Comp. Physiol. 2002, 283:R905-R910.
32. Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J.r.-C., Hebebrand J., Theisen F.M. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J. Psychiatr. Res. 2009, 43:620-626.
33. Guan X.-M., Yu H., Palyha O.C., McKee K.K., Feighner S.D., Sirinathsinghji D.J.S., Smith R.G., Van der Ploeg L.H.T., Howard A.D. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol. Brain Res. 1997, 48:23-29.
34. Harrold J.A., Dovey T., Cai X.-J., Halford J.C.G., Pinkney J. Autoradiographic analysis of ghrelin receptors in the rat hypothalamus. Brain Res. 2008, 1196:59-64.
35. Heath R.B., Jones R., Frayn K.N., Robertson M.D. Vagal stimulation exaggerates the inhibitory ghrelin response to oral fat in humans. J. Endocrinol. 2004, 180:273-281.
36. Himmerich H., Fulda S., Künzel H.E., Pfennig A., Dzaja A., Cummings D.E., Pollmächer T. Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 2005, 52:11-16.
37. Hosoda H., Kangawa K. The autonomic nervous system regulates gastric ghrelin secretion in rats. Regul. Peptides 2008, 146:12-18.
38. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., Kanai A., Kase A., Uchikado H., Hirayasu Y. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J. Psychopharmacol. 2006, 20:75-79.
39. Jerlhag E., Egecioglu E., Dickson S.L., Andersson M., Svensson L., Engel J.A. Preclinical study: ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: implications for its involvement in brain reward. Addict. Biol. 2006, 11:45-54.
40. Jerlhag E., Egecioglu E., Dickson S.L., Douhan A., Svensson L., Engel J.A. Preclinical study: ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict. Biol. 2007, 12:6-16.
41. Jiang H., Betancourt L., Smith R.G. Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol. Endocrinol. 2006, 20:1772-1785.
42. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr. Res. 2008, 100:70-85.
43. Kamegai J., Tamura H., Shimizu T., Ishii S., Sugihara H., Oikawa S. Effects of insulin, leptin, and glucagon on ghrelin secretion from isolated perfused rat stomach. Regul. Peptides 2004, 119:77-81.
44. Kane J.M., Fleischhacker W.W., Hansen L., Perlis R., Pikalov A., Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatr. 2009, 70:627-643.
45. Kern A., Albarran-Zeckler R., Walsh H., Smith R. Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 2012, 73:317-332.
46. Kim B.-J., Sohn J.-W., Park C.-S., Hahn G.-H., Koo J., Noh Y.-D., Lee C.-S. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J. Korean Med. Sci. 2008, 23:685-690.
47. Kim H.-J., Kobayashi M., Sasaki T., Kikuchi O., Amano K., Kitazumi T., Lee Y.-S., Yokota-Hashimoto H., Susanti V.Y., Kitamura Y.I., Nakae J., Kitamura T. Overexpression of FoxO1 in the hypothalamus and pancreas causes obesity and glucose intolerance. Endocrinology 2012, 153:659-671.
48. Kim M.-S., Pak Y.K., Jang P.-G., Namkoong C., Choi Y.-S., Won J.-C., Kim K.-S., Kim S.-W., Kim H.-S., Park J.-Y., Kim Y.-B., Lee K.-U. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat. Neurosci. 2006, 9:901-906.
49. Kineman R.D., Kamegai J., Frohman L.A. Growth hormone (GH)-releasing hormone (GHRH) and the GH secretagogue (GHS), L692,585, differentially modulate rat pituitary GHS receptor and GHRH receptor messenger ribonucleic acid levels. Endocrinology 1999, 140:3581-3586.
50. Kitamura T., Feng Y., Ido Kitamura Y., Chua S.C., Xu A.W., Barsh G.S., Rossetti L., Accili D. Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat. Med. 2006, 12:534-540.
51. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
52. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
53. Lage R., Vázquez M.J., Varela L., Saha A.K., Vidal-Puig A., Nogueiras R., Diéguez C., López M. Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J. 2010, 24:2670-2679.
54. le Roux C.W., Neary N.M., Halsey T.J., Small C.J., Martinez-Isla A.M., Ghatei M.A., Theodorou N.A., Bloom S.R. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J. Clin. Endocr. Metab. 2005, 90:4521-4524.
55. Lee H.-M., Wang G., Englander E.W., Kojima M., Greeley G.H. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 2002, 143:185-190.
56. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
57. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Asenjo Lobos C., Schwarz S., Davis J.M. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatr. 2009, 166:152-163.
58. Li Y., Wu X., Zhao Y., Chen S., Owyang C. Ghrelin acts on the dorsal vagal complex to stimulate pancreatic protein secretion. Am. J. Physiol., Gastrointest. Liver Physiol. 2006, 290:G1350-G1358.
59. Li Z., Huang M., Ichikawa J., Dai J., Meltzer H.Y. N-Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 2005, 30:1986-1995.
60. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
61. López M., Lage R., Saha A.K., Pérez-Tilve D., Vázquez M.J., Varela L., Sangiao-Alvarellos S., Tovar S., Raghay K., Rodríguez-Cuenca S., Deoliveira R.M., Castañeda T., Datta R., Dong J.Z., Culler M., Sleeman M.W., Álvarez C.V., Gallego R., Lelliott C.J., Carling D., Tschöp M.H., Diéguez C., Vidal-Puig A. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 2008, 7:389-399.
62. Lu S., Guan J.L., Wang Q.P., Uehara K., Yamada S., Goto N., Date Y., Nakazato M., Kojima M., Kangawa K., Shioda S. Immunocytochemical observation of ghrelin-containing neurons in the rat arcuate nucleus. Neurosci. Lett. 2001, 321:157-160.
63. Martins L., Fernandez-Mallo D., Novelle M.G., Vazquez M.J., Tena-Sempere M., Nogueiras R., Lopez M., Dieguez C. Hypothalamic mTOR Signaling Mediates the Orexigenic Action of Ghrelin. PLoS ONE 2012, 7:e46923.
64. Mathews J., Newcomer J.W., Mathews J.R., Fales C.L., Pierce K.J., Akers B.K., Marcu I., Barch D.M. Neural correlates of weight gain with olanzapine. Arch. Gen. Psychiatry 2012, 69:1226-1237.
65. Miao Y., Xia Q., Hou Z., Zheng Y., Pan H., Zhu S. Ghrelin protects cortical neuron against focal ischemia/reperfusion in rats. Biochem. Biophys. Res. Commun. 2007, 359:795-800.
66. Monda M., Viggiano A., Viggiano A., Mondola R., Viggiano E., Messina G., Tafuri D., De Luca V. Olanzapine blocks the sympathetic and hyperthermic reactions due to cerebral injection of orexin A. Peptides 2008, 29:120-126.
67. Monteleone P., Bencivenga R., Longobardi N., Serritella C., Maj M. Differential responses of circulating ghrelin to high-fat or high-carbohydrate meal in healthy women. J. Clin. Endocr. Metab. 2003, 88:5510-5514.
68. Murashita M., Inoue T., Kusumi I., Nakagawa S., Itoh K., Tanaka T., Izumi T., Hosoda H., Kangawa K., Koyama T. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatr. Clin. Neurosci. 2007, 61:54-58.
69. Murashita M., Kusumi I., Hosoda H., Kangawa K., Koyama T. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology 2007, 32:777-784.
70. Murashita M., Kusumi I., Inoue T., Takahashi Y., Hosoda H., Kangawa K., Koyama T. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005, 30:106-110.
71. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
72. Naleid A.M., Grace M.K., Cummings D.E., Levine A.S. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides 2005, 26:2274-2279.
73. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatr. 2008, 13:27-35.
74. Nogueiras R., López M., Lage R., Perez-Tilve D., Pfluger P., Mendieta-Zerón H., Sakkou M., Wiedmer P., Benoit S.C., Datta R., Dong J.Z., Culler M., Sleeman M., Vidal-Puig A., Horvath T., Treier M., Diéguez C., Tschöp M.H. Bsx, a novel hypothalamic factor linking feeding with locomotor activity, is regulated by energy availability. Endocrinology 2008, 149:3009-3015.
75. Nogueiras R., Tovar S., Mitchell S.E., Rayner D.V., Archer Z.A., Dieguez C., Williams L.M. Regulation of growth hormone secretagogue receptor gene expression in the arcuate nuclei of the rat by leptin and ghrelin. Diabetes 2004, 53:2552-2558.
76. Palik E., Birkás K.D., Faludi G., Karádi I., Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res. Clin. Pract. 2005, 68:S60-S64.
77. Palmiter R.D. Is dopamine a physiologically relevant mediator of feeding behavior?. Trends Neurosci. 2007, 30:375-381.
78. Pan W., Tu H., Kastin A.J. Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides 2006, 27:911-916.
79. Perez-Iglesias R., Vazquez-Barquero J.L., Amado J.A., Berja A., Garcia-Unzueta M.T., Pelayo-Terán J.M., Carrasco-Marín E., Mata I., Crespo-Facorro B. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J. Clin. Psychopharmacol. 2008, 28:289-295. 10.1097/JCP.1090b1013e318172b318178e318176.
80. Popovic V., Doknic M., Maric N., Pekic S., Damjanovic A., Miljic D., Popovic S., Miljic N., Djurovic M., Jasovic-Gasic M., Dieguez C., Casanueva F.F. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007, 85:249-256.
81. Ramirez S., Martins L., Jacas J., Carrasco P., Pozo M., Clotet J., Serra D., Hegardt F.G., Dieguez C., Lopez M., Casals N. Hypothalamic ceramide levels regulated by CPT1C mediate the orexigenic effect of ghrelin. Diabetes 2013.
82. Rediger A., Piechowski C.L., Yi C.-X., Tarnow P., Strotmann R., Grüters A., Krude H., Schöneberg T., Tschöp M.H., Kleinau G., Biebermann H. Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors. J. Biol. Chem. 2011, 286:39623-39631.
83. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol. Therapeut. 2008, 125:169-179.
84. Roerig J.L., Steffen K.J., Mitchell J.E., Crosby R.D., Gosnell B.A. A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels. J. Clin. Psychopharmacol. 2008, 28:21-26. 10.1097/jcp.1090b1013e3181613325.
85. Sakata I., Yamazaki M., Inoue K., Hayashi Y., Kangawa K., Sakai T. Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion. Neurosci. Lett. 2003, 342:183-186.
86. Sakkou M., Wiedmer P., Anlag K., Hamm A., Seuntjens E., Ettwiller L., Tschöp Matthias H., Treier M. A role for brain-specific homeobox factor Bsx in the control of hyperphagia and locomotory behavior. Cell Metab. 2007, 5:450-463.
87. Sánchez J., Oliver P., Palou A., Picó C. The inhibition of gastric ghrelin production by food intake in rats is dependent on the type of macronutrient. Endocrinology 2004, 145:5049-5055.
88. Sawchenko P.E., Swanson L.W. Central noradrenergic pathways for the integration of hypothalamic neuroendocrine and autonomic responses. Science 1981, 214:685-687.
89. Schellekens H., Dinan T.G., Cryan J.F. Lean mean fat reducing ghrelin machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity. Neuropharmacology 2010, 58:2-16.
90. Schellekens H., Finger B.C., Dinan T.G., Cryan J.F. Ghrelin signalling and obesity: at the interface of stress, mood and food reward. Pharmacol. Therapeut. 2012, 135:316-326.
91. Schellekens H., van Oeffelen W.E.P.A., Dinan T.G., Cryan J.F. Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling. J. Biol. Chem. 2013, 288:181-191.
92. Sentissi O., Epelbaum J., Olie J.-P., Poirier M.-F. Leptin and Ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr. Bull. 2008, 34:1189-1199.
93. Shimizu-Albergine M., Ippolito D.L., Beavo J.A. Downregulation of fasting-induced cAMP response element-mediated gene induction by leptin in neuropeptide Y neurons of the arcuate nucleus. J. Neurosci. 2001, 21:1238-1246.
94. Shrestha Y.B., Wickwire K., Giraudo S.Q. Direct effects of nutrients, acetylcholine, CCK, and insulin on ghrelin release from the isolated stomachs of rats. Peptides 2009, 30:1187-1191.
95. Skrede S., Fernø J., Vázquez M.J., Fjær S., Pavlin T., Lunder N., Vidal-Puig A., Diéguez C., Berge R.K., López M., Steen V.M. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int. J. Neuropsychopharmacol. 2012, 15:163-179.
96. Smith R.C., Rachakonda S., Dwivedi S., Davis J.M. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. Psychiatry Res. 2012, 199:159-163.
97. Smith S. Gender differences in antipsychotic prescribing. Int. Rev. Psychiatry 2010, 22:472-484.
98. Stefanidis A., Verty A.N.A., Allen A.M., Owens N.C., Cowley M.A., Oldfield B.J. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity 2009, 17:16-24.
99. Tanaka K., Morinobu S., Ichimura M., Asakawa A., Inui A., Hosoda H., Kangawa K., Yamawaki S. Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. Prog. Neuro Psychopharmacol. 2008, 32:1527-1532.
100. Tang-Christensen M., Vrang N., Ortmann S., Bidlingmaier M., Horvath T.L., Tschop M. Central administration of ghrelin and agouti-related protein (83-132) increases food intake and decreases spontaneous locomotor activity in rats. Endocrinology 2004, 145:4645-4652.
101. Theisen F.M., Gebhardt S., Brömel T., Otto B., Heldwein W., Heinzel-Gutenbrunner M., Krieg J.C., Remschmidt H., Tschöp M., Hebebrand J. A prospective study of serum ghrelin levels in patients treated with clozapine. J. Neural Transm. 2005, 112:1411-1416.
102. Togo T., Hasegawa K., Miura S., Hosojima H., Kojima K., Shoji M., Kase A., Uchikado H., Iseki E., Kosaka K. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berlin) 2004, 172:230-232.
103. Toshinai K., Mondal M.S., Nakazato M., Date Y., Murakami N., Kojima M., Kangawa K., Matsukura S. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem. Biophys. Res. Commun. 2001, 281:1220-1225.
104. Tschop M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407:908-913.
105. Tschop M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50:707-709.
106. van der Zwaal E.M., Luijendijk M.C.M., Evers S.S., la Fleur S.E., Adan R.A.H. Olanzapine affects locomotor activity and meal size in male rats. Pharmacol. Biochem. Behav. 2010, 97:130-137.
107. van der Zwaal E.M., Merkestein M., Lam Y.K., Brans M.A.D., Luijendijk M.C.M., Bok L.I.H., Verheij E.R., la Fleur S.E., Adan R.A.H. The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature. Int. J. Obes. 2012, 36:254-261.
108. Velasquez D.A., Martinez G., Romero A., Vazquez M.J., Boit K.D., Dopeso-Reyes I.G., Lopez M., Vidal A., Nogueiras R., Dieguez C. The central sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 2011, 60:1177-1185.
109. Vidarsdottir S., Roelfsema F., Streefland T., Holst J.J., Rehfeld J.F., Pijl H. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur. J. Endocrinol. 2010, 162:75-83.
110. Weston-Green K., Huang X.-F., Deng C. Sensitivity of the female rat to olanzapine-induced weight gain - far from the clinic?. Schizophr. Res. 2010, 116:299-300.
111. Weston-Green K., Huang X.-F., Deng C. Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav. Brain Res. 2011, 217:337-346.
112. Weston-Green K., Huang X.-F., Deng C. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS ONE 2012, 7:e33548.
113. Weston-Green K., Huang X.-F., Lian J., Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur. Neuropsychopharmacol. 2012, 22:364-373.
114. Williams D.L., Grill H.J., Cummings D.E., Kaplan J.M. Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 2003, 144:5184-5187.
115. Yang J., Brown M.S., Liang G., Grishin N.V., Goldstein J.L. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008, 132:387-396.
116. Yamauchi T., Tatsumi K., Makinodan M., Kimoto S., Toritsuka M., Okuda H., Kishimoto T., Wanaka A. Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus. Neurochemistry International 2010, 57:565-571.
117. Zaniolo K., Sapieha P., Shao Z., Stahl A., Zhu T., Tremblay S., Picard E., Madaan A., Blais M., Lachapelle P., Mancini J., Hardy P., Smith L.E.H., Ong H., Chemtob S. Ghrelin modulates physiologic and pathologic retinal angiogenesis through GHSR-1a. Invest. Ophthalmol. Vis. Sci. 2011, 52:5376-5386.
118. Zhang Q., He M., Wang H., Lian J., Deng C., Huang X.-F. Time-dependent alterations of hypothalamic energy regulatory network by olanzapine in rats. Australian Neuroscience Society 32nd Annual Meeting, Jan-Feb 2012 2012.